

# The effect of telomere length, a marker of biological aging, on bone mineral density in elderly population

N. L. S. Tang · J. Woo · E. W. C. Suen · C. D. Liao ·  
J. C. S. Leung · P. C. Leung

Received: 5 January 2009 / Accepted: 27 March 2009 / Published online: 13 May 2009  
© International Osteoporosis Foundation and National Osteoporosis Foundation 2009

## Abstract

**Summary** Telomere length (TL), as a reflection of aging and inflammatory processes, may be associated with bone mineral density (BMD). This study examines the association between TL and BMD cross-sectionally and the rate of bone loss over a 4-year period in 1,867 Chinese elderly community living subjects. After adjusting for confounding factors, no association was observed with BMD or bone loss. The decline in BMD with aging is not reflected by corresponding changes in telomere length.

**Introduction** Bone mineral density (BMD) is influenced by the dynamics of aging, inflammatory, and bone remodeling processes. Telomere length (TL) is a reflection of the former two processes and may also be associated with bone loss.

**Methods** Hip BMD was measured in 1,867 Chinese elderly community living subjects and the relationship between leukocyte TL measured using quantitative real-time polymerase chain reaction, and bone loss after 4 years was examined.

**Results** Women had greater bone loss than men. In women, age of menopause, menarche, estrogen treatment/replacement therapy, and history of previous fracture were also among the significant covariates. However, in multivariate analyses, TL was not associated with BMD in either sex.

**Conclusions** TL was not associated with either baseline BMD or bone loss over 4 years and accounted for less than 1.6% of the baseline BMD.

**Keywords** Bone loss · Bone mineral density · Elderly · Telomere length

N. L. S. Tang · C. D. Liao  
Department of Chemical Pathology, Faculty of Medicine,  
The Chinese University of Hong Kong,  
Hong Kong, China

J. Woo · E. W. C. Suen  
Department of Medicine & Therapeutics, Faculty of Medicine,  
The Chinese University of Hong Kong,  
Hong Kong, China

J. C. S. Leung · P. C. Leung  
Jockey Club Centre for Osteoporosis Care and Control,  
Faculty of Medicine, The Chinese University of Hong Kong,  
Hong Kong, China

J. Woo (✉)  
Department of Medicine & Therapeutics,  
Prince of Wales Hospital,  
Shatin, NT, Hong Kong, China  
e-mail: jeanwoowong@cuhk.edu.hk

## Introduction

Osteoporosis represents a major public health concern in aging societies, fragility fractures having the highest impact on both quality of life and health care systems worldwide [1]. Bone mineral density measurement (BMD) in hip and spine is used in the diagnosis of osteoporosis [2]. The association between low BMD and risk of bone fractures has been reported extensively [3–7]. In a recent review, advanced age, smoking, low body weight, physical limitations, and prevalent fracture (after age 50) were consistent risk factors for osteoporosis [8]. BMD declines with age, chronological age being a major determinant of BMD.

Recent studies into the mechanism of aging revealed various processes leading to replicative senescence [9].

Critically short telomere length is a marker of biological aging [10]. In addition to natural replicative attrition, the inflammatory process also enhances the rate of telomere length (TL) attrition, such that association between TL and chronic inflammatory states has been documented. Telomeres consist of short unique repeated DNA sequence (TTAGGG), and specialized proteins are located at both ends of linear chromosomes in humans. They act as the cap of the chromosome and maintain genomic integrity by preventing chromosome fusions and atypical recombination [11]. Due to the end replication problem of DNA, telomeres shorten in each cell division. Therefore, telomere length and its attrition reflect on cellular replication history and cellular senescence and is considered a new marker of biological aging, representing a new but different dimension of the aging process from chronological age. With respect to bone health, replicative aging of osteoblast precursor cells has been demonstrated and shown to be associated with telomere attrition in this cell type [12]. Furthermore, exacerbated telomere erosion is also a common feature in other diseases associated with chronic inflammation such as autoimmune and ischemic heart diseases [13, 14].

There are genetic and environmental determinants for BMD. Genetic determinants of BMD have been described extensively [15–18]. Genetic studies include candidate gene association, familial linkage, and genome-wide association (GWA) studies [19, 20]. On the other hand, smoking, immobility, and chronic inflammatory conditions have been documented as common environmental risk factors associated with osteoporosis. It is interesting to find that pro-inflammatory genes were also associated with osteoporosis in the latest GWA studies. For example, one of the pre-disposition genes for osteoporosis is the receptor activator of nuclear factor  $\kappa$ B ligand (RANKL) [21]. Chronic inflammation with activated T cells induced the expression of RANKL gene and enhanced bone resorption. These results indicate a strong role of inflammatory response in bone loss [22–24].

Since both bone loss and telomere attrition have been linked to inflammation, it has been hypothesized that short telomere length is a risk factor for osteoporosis. In a small cohort of 84 elderly men, telomere length was not associated with baseline forearm BMD, but it was associated with bone loss at a borderline significance ( $P=0.03$ ) [25]. In another study of 2,150 women aged between 18 and 80, telomere length was significantly correlated with forearm and spine BMD [26]. These findings suggest that telomere length may be a predictor or marker for osteoporosis and impending bone loss in aging populations. To date, there have not been any studies in Chinese populations. As part of a territory-wide study on bone health in older people aged 65 and over, we examined the association between

telomere length, baseline BMD, and its change over 4 years.

## Methods

### Study subjects

A community cohort of 2,000 men and 2,000 women aged 65 or above were recruited from community centers for the elderly and housing estates in Hong Kong. In the recruitment process, about one third of the volunteers were stratified to each of the age groups of 65–69, 70–74, and 75 or above. DNA samples were available and analyzed in a subgroup of 963 men and 904 women. At recruitment, participants completed a detailed questionnaire containing information on demographics, medical and drug histories, smoking status, and dietary intake [27]. The presence or absence of diseases was reported as diagnosed by their doctors. The study had been approved by the Clinical Research Ethics Committee of the Chinese University of Hong Kong, and informed consent was obtained from all participants.

Bone mineral density at the hip and femoral neck was measured using dual X-ray absorptiometry (DXA) by Hologic QDR-4,500 W densitometers (Hologic, Waltham, MA, USA). The coefficient of variation (in vivo) in our laboratory was 0.7% at the hip [28]. Clinical osteoporosis at the hip was defined using the WHO criteria of a T-score less than  $-2.5$ . Body weight was measured with subjects wearing a light gown using the Physician Balance Beam Scale (Healthometer, Illinois, USA). Height was measured by the Holtain Harpenden stadiometer (Holtain, Crosswell, UK). Body mass index (BMI) was calculated by dividing the weight in kilograms by the square of the height in meters.

Information about usual level of physical activity was also recorded using the Physical Activity Scale of the Elderly (PASE). This is a 12-item scale measuring the average number of hours per day spent in leisure, household, and occupational physical activities over the previous 7-day period. Activity weights for each item were determined based on the amount of energy expended, and each item score was calculated by multiplying the activity weight by activity daily frequency. A summary score of all the items reflect the daily physical activity level [29].

### Four-year follow-up

All participants were invited for a 4-year follow up. During the follow-up examination, information on disease status and fracture history was recorded. Anthropometry and BMD were also measured. Changes in BMD were determined

during the 4-year period. Seven hundred twenty-seven men and 735 women came back for follow-up.

#### Telomere length measurement by quantitative real-time polymerase chain reaction

The principle of the laboratory method has been previously described [27]. In short, DNA was extracted in the peripheral blood by phenol-chloroform method and stored at  $-80^{\circ}\text{C}$  with concentration  $>100\text{ ng}/\mu\text{l}$  (whereas working samples of  $20\text{ ng}/\mu\text{l}$  were prepared before analysis). Telomere length measurement followed the method published by Cawthon [30] with modification [31]. Unlike the traditional method using terminal restriction fragment (TRF) analysis, this method used the technique of quantitative real-time polymerase chain reaction (qRT-PCR), which has the advantage of high throughput, time-saving, and reproducible estimation of telomere length [30, 32–34]. Roche LightCycler 480 (Roche, Mannheim, Germany) was used to perform the qRT-PCR with primer sequences obtained from Cawthon [31]. The  $T/S$  ratio ( $C_{t(\text{telomere assay})}/C_{t(\text{single-copy gene assay})}$ ) was used to assess the relative length of telomere, while  $C_t$  is the fractional cycle number for a threshold fluorescence level to be reached during qRT-PCR. The  $T/S$  ratio ( $\Delta\Delta\text{Ct}$ ) was then plotted against a standard calibration curve using samples with predetermined telomere lengths to obtain the telomere length in unit of kilobase pairs (kbp). The coefficient of variation % (CV%) of the  $C_t$  mea-

surements of the telomere and the single-copy gene probes were 3.6% and 1.8%, respectively. Two control samples were analyzed in duplicates in each batch of assays; one sample was collected from volunteers of age of 20s representing a long telomere control (long QC, by TRF=11.6 kbp) and another one from an elderly subject representing a short telomere control (short QC, by TRF=8.2 kbp). Within-batch and between-batch analytical imprecisions were determined from over 20 batches of assays using these two samples. The within-batch and between-batch CV% of  $\Delta\Delta\text{Ct}$  was 11.9% and 11.2% for the long QC sample. For the short QC sample, they were 8.1% and 14.2%, respectively.

A calibration curve was drawn by using  $\Delta\Delta\text{Ct}$  values obtained from five different samples of predetermined TL by TRF method. The coefficient of determination ( $R^2$ ) of the linear correlation between TL by TRF method and  $\Delta\Delta\text{Ct}$  was 0.63, which was similar to that reported ( $R^2=0.68$ ) in the original description of the  $\Delta\Delta\text{Ct}$  method by Cawthon [22]. Calibration to TL in kbp was carried out independently for each batch which in a way partially corrected for between-batch variation in determination of  $\Delta\Delta\text{Ct}$  and TL. After calibration to TL in kbp, the within-batch and between-batch CV% of TL was 8.5% and 7.5% for the long QC sample. For the short QC sample, they were 6.3% and 6.1%, respectively. A reduction of between-batch CV% was noted which reflected a partial correction of the between-batch variation in the calibration process.

**Table 1** Characteristics of the study cohort at baseline

Characteristics	Mean $\pm$ SD or N (%)		<i>P</i> for gender difference <sup>a</sup>
	Male ( <i>N</i> =963)	Female ( <i>N</i> =904)	
Age	72.8 $\pm$ 5.0	71.8 $\pm$ 5.1	
65–69 age group (%)	287 (29.8%)	360 (39.8%)	
70–74 age group (%)	342 (35.5%)	306 (33.8%)	
$\geq 75$ age group (%)	334 (34.7%)	238 (26.3%)	
BMI ( $\text{kg}/\text{m}^2$ )	23.4 $\pm$ 3.08	23.9 $\pm$ 3.5	0.001
Telomere length (kb)	5.40 $\pm$ 1.62	5.95 $\pm$ 2.23	<0.001
PASE score	94.9 $\pm$ 49.4	90.7 $\pm$ 35.4	0.035
Calcium intake (g/day)	0.625 $\pm$ 0.302	0.578 $\pm$ 0.282	<0.001
Smoking (current or ex-smoker)(%)	599 (62.2%)	76 (8.4%)	<0.001
History of CHD (%)	97 (10.1%)	78 (8.6%)	0.302
History of fracture (%)	132 (13.7%)	180 (19.9%)	<0.001
Reproductive history in women subjects			
Age of menarche	–	15.9 $\pm$ 2.4	–
Age of menopause	–	49.2 $\pm$ 4.7	–
Number of children	–	4.8 $\pm$ 2.3	–
History of breast feeding (%)	–	752 (83.2%)	–
History of estrogen treatment (%)	–	37 (4.3%)	–

SD standard deviation, BMI body mass index, PASE Physical Activity Score for Elderly, CHD coronary heart diseases

<sup>a</sup> Student's *t* test or chi-square test as appropriate

**Table 2** BMDs of the study cohort at baseline, at 4-year follow-up, and the changes in BMD after 4 years

BMDs (g/cm <sup>2</sup> )	Mean±SD or N (%)		P for gender difference <sup>a</sup>
	Male	Female	
<b>Hip BMD</b>			
At baseline	N=963 0.857±0.126	N=904 0.709±0.118	<0.001
At 4-year follow-up	N=727 0.859±0.129	N=735 0.701±0.116	<0.001
Changes in BMD after 4 years	-0.007±0.029	-0.016±0.031	<0.001
# of individuals with bone loss	414 (56.9%)	516 (70.2%)	<0.001
<b>Femoral neck BMD</b>			
At baseline	N=963 0.680±0.109	N=904 0.585±0.101	<0.001
At 4-year follow-up	N=727 0.685±0.110	N=735 0.580±0.102	<0.001
Changes in BMD after 4 years	-0.004±0.034	-0.011±0.040	<0.001
# of individual with bone loss	386 (53.1%)	499 (67.9%)	<0.001

BMD bone mineral density

<sup>a</sup> Student's *t* test or chi-square test as appropriate

### Statistical analysis

Descriptive and analytical statistics were carried out using SPSS v15.0 (SPSS, Chicago, USA). Analytical errors of  $\Delta\Delta\text{Ct}$  and TL were partitioned into within-batch and between-batch errors using a BASIC program [35]. Changes in hip BMD and TL were normally distributed, while heteroscedasticity was not demonstrated in the residual plots of regressions for BMD changes. This allows associations between telomere length and BMD at various sites to be analyzed using multivariate linear models. Covariates of TL and BMD were adjusted in the multivariate regression for both sexes, which included age, BMI,

PASE score, daily dietary vitamin D intake, history of smoking, heart diseases, and fracture. In addition, age of menarche, age of menopause, numbers of children, history of breast feeding, and estrogen treatment were also included as covariates for women [36–38]. PASE scores were grouped by deciles in the multivariate analysis. *P* value less than 0.05 were considered as statistically significant.

### Results

At baseline, 963 men and 904 women TL were measured in using real-time quantitative PCR assay. Characteristics of

**Table 3** BMDs of the study cohort, separated by age groups, at baseline and the changes in BMD after 4 years

	Age groups	Male			Female		
		N	Mean ± SD	P <sup>a</sup>	N	Mean ± SD	P <sup>a</sup>
Baseline BMDs		Total N=963			Total N=904		
Hip BMD	65–69	287	0.866±0.124	0.007	360	0.741±0.110	<0.001
	70–74	342	0.866±0.119		306	0.715±0.117	
	≥75	334	0.839±0.134		238	0.652±0.109	
Femoral neck BMD	65–69	287	0.693±0.107	0.004	360	0.617±0.095	<0.001
	70–74	342	0.686±0.106		306	0.584±0.099	
	≥75	334	0.665±0.113		238	0.539±0.093	
Changes in BMDs after 4 years		Total N=727			Total N=735		
Hip BMD	65–69	240	-0.004±0.026	0.004	308	-0.013±0.032	0.011
	70–74	278	-0.004±0.028		251	-0.015±0.029	
	≥75	209	-0.016±0.032		176	-0.021±0.032	
Femoral neck BMD	65–69	240	-0.003±0.030	0.049	308	-0.011±0.050	0.360
	70–74	278	-0.001±0.034		251	-0.008±0.033	
	≥75	209	-0.008±0.039		176	-0.014±0.031	

<sup>a</sup> Analysis of variance test comparing the BMD or BMD loss among the three age groups.




Fig. 1 Distribution of telomere length in each age group

the subjects are shown in Table 1. Women had higher body mass index compared with men. Hip and femoral BMD were higher in men by 16% to 21% compared with women (Table 2). After dividing subjects into three 5-year interval age groups, similar percentage differences between the two sexes were confirmed (Table 3). During follow-up, 75% of men and 81% of women had returned at 4 years. Mean hip BMD loss was 0.007 g/cm<sup>2</sup> in men and greater in women (0.016 g/cm<sup>2</sup>; *P*<0.001, Table 2). Similarly, loss in femoral neck BMD was greater in women (*P*<0.001). BMD loss was highest in the oldest age group (≥75 year old).

Mean telomere length was 5.40 and 5.95 kb for men and women, respectively. Women had longer telomere than men (*P*<0.001; Table 1). There was a general decreasing trend in TL with age in men, and the correlation between TL and age was statistically significant

Table 4 Multiple linear regression for association between telomere length and covariants with baseline BMDs

Variables	Baseline BMDs			
	Hip BMD		Femoral neck BMD	
	β (95% CI)	<i>P</i>	β (95% CI)	<i>P</i>
<b>Male (N=963)</b>				
Age	-0.002 (-0.003, 0.000)	0.009	-0.002 (-0.003, -0.001)	0.003
BMI	0.020 (0.018, 0.023)	<0.001	0.016 (0.014, 0.018)	<0.001
PASE score in deciles	0.003 (0.000, 0.005)	0.034	0.002 (0.000, 0.004)	0.056
Calcium intake (g/day)	0.015 (-0.008, 0.038)	0.201	0.017 (-0.003, 0.037)	0.097
History of smoking	-0.026 (-0.040, -0.011)	<0.001	-0.014 (-0.026, -0.001)	0.033
History of CHD	-0.012 (-0.035, 0.011)	0.303	-0.015 (-0.035, 0.006)	0.157
History of fracture	-0.015 (-0.035, 0.005)	0.143	-0.016 (-0.034, 0.001)	0.066
Telomere length (kb)	0.002 (-0.003, 0.006)	0.424	0.003 (-0.001, 0.007)	0.112
	Model R <sup>2</sup> =0.282		Model R <sup>2</sup> =0.249	
<b>Female (N=904)</b>				
Age	-0.005 (-0.007, -0.004)	<0.001	-0.005 (-0.006, -0.004)	<0.001
BMI	0.016 (0.014, 0.018)	<0.001	0.012 (0.011, 0.014)	<0.001
PASE score in deciles	0.001 (-0.001, 0.004)	0.221	0.001 (-0.001, 0.003)	0.189
Calcium intake (g/day)	0.046 (0.024, 0.068)	<0.001	0.037 (0.018, 0.056)	<0.001
History of smoking	-0.005 (-0.028, 0.018)	0.665	0.001 (-0.019, 0.021)	0.930
History of CHD	0.002 (-0.020, 0.024)	0.844	0.005 (-0.015, 0.024)	0.622
History of fracture	-0.021 (-0.036, -0.005)	0.009	-0.020 (-0.034, -0.006)	0.004
Age of menarche	-0.002 (-0.005, 0.001)	0.139	-0.003 (-0.005, -0.001)	0.013
Age of menopause	0.002 (0.001, 0.003)	0.005	0.001 (0.000, 0.003)	0.020
Pregnancy (# of children)	-0.002 (-0.005, 0.001)	0.133	-0.002 (-0.005, 0.000)	0.100
History of Breast feeding	0.003 (-0.014, 0.020)	0.702	0.013 (-0.003, 0.028)	0.106
History of Estrogen treatment	0.039 (0.008, 0.071)	0.015	0.030 (0.002, 0.058)	0.034
Telomere length (kb)	0.000 (-0.003, 0.003)	0.988	-0.001 (-0.003, 0.002)	0.458
	Model R <sup>2</sup> =0.366		Model R <sup>2</sup> =0.332	

Multiple linear regressions adjusted for age, BMI, PASE score in deciles, daily calcium intake, history of smoking, CHD and fracture (for men and women); age of menopause, age of menarche, number of children, history of breast feeding, history of estrogen treatment (women only)

CI confidence interval, NS not significant

( $P=0.037$ ; Fig. 1). There was no correlation between TL and age in women ( $P=0.784$ ).

Table 4 shows the regression coefficients of the association between telomere length, other covariants, and hip and femoral neck BMD at baseline. Age and BMI showed the strongest association in both sexes. In women, age of menopause, age of menarche, estrogen treatment/replacement therapy, and history of previous fracture were also significant covariates. In addition, PASE score and dietary calcium intake were also significantly correlated with BMD at baseline. However, in these multivariate analyses, TL was not associated with BMD in either sex.

To examine if TL could predict bone loss, the analysis was repeated using change in BMD after 4 years (Table 5). Age was the only significant factor associated with change in hip BMD. PASE score was significantly correlated with bone loss at both total hip and femoral neck in men, while history of fracture was also associated with change in hip BMD in women. TL was not associated with change in BMD in either site in men or women.

To further explore the association between baseline or loss of BMD and TL, a subgroup analysis was performed. In order to minimize the effect of chronological age, subjects were stratified by sex and age groups of 5 years (65–69, 70–74, and 75 and above). The effect of TL and covariants were analyzed by linear regression in each of these three different age groups. Only a weak association between TL and baseline hip and femoral neck BMD was found in men between 70 and 74 years (Table 6). However, TL only accounts for up to 1.6% of the variance of baseline BMD. The effect of TL on the risk of osteoporosis was explored by logistic regressions with correction for confounding covariates. In both whole sample and age group stratified analyses, TL was not a significant risk factor for osteoporosis of the hip in either sex (Table 7).

## Discussion

Two recent clinical studies suggest that leukocyte telomere length could be a marker of biological aging of bone and

**Table 5** Multiple linear regressions for association between telomere length and covariants with changes in BMDs after 4 years

Variables	Changes in BMDs after 4years			
	Hip BMD		Femoral neck BMD	
	$\beta$ (95% CI)	<i>P</i>	$\beta$ (95% CI)	<i>P</i>
<b>Male (N=727)</b>				
Age	-0.001 (-0.001, 0.000)	<0.001	0.000 (-0.001, 0.000)	0.470
BMI	0.000 (0.000, 0.001)	0.409	0.000 (-0.001, 0.000)	0.297
PASE score in deciles	0.001 (0.000, 0.002)	0.034	0.001 (0.000, 0.002)	0.026
Calcium intake (g/day)	0.005 (-0.002, 0.012)	0.130	0.005 (-0.003, 0.014)	0.216
History of smoking	-0.003 (-0.007, 0.001)	0.137	-0.004 (-0.009, 0.001)	0.115
History of CHD	-0.004 (-0.011, 0.003)	0.267	0.004 (-0.004, 0.012)	0.351
History of fracture	-0.002 (-0.008, 0.004)	0.561	-0.003 (-0.010, 0.005)	0.457
Telomere length (kb)	0.001 (0.000, 0.002)	0.090	0.001 (-0.001, 0.003)	0.208
	Model $R^2=0.046$		Model $R^2=0.020$	
<b>Female (N=735)</b>				
Age	-0.001 (-0.001, 0.000)	0.003	0.000 (-0.001, 0.000)	0.330
BMI	-0.001 (-0.001, 0.000)	0.071	0.000 (-0.001, 0.001)	0.704
PASE score in deciles	0.000 (-0.001, 0.001)	0.495	0.000 (-0.001, 0.001)	0.552
Calcium intake (g/day)	0.001 (-0.007, 0.009)	0.836	0.005 (-0.006, 0.016)	0.355
History of smoking	-0.005 (-0.014, 0.003)	0.234	-0.001 (-0.012, 0.011)	0.870
History of CHD	0.001 (-0.007, 0.010)	0.728	0.002 (-0.009, 0.013)	0.679
History of fracture	0.006 (0.000, 0.012)	0.036	0.005 (-0.002, 0.013)	0.149
Age of menarche	0.000 (-0.001, 0.001)	0.887	0.000 (-0.001, 0.002)	0.607
Age of menopause	0.000 (-0.001, 0.001)	0.377	0.000 (-0.001, 0.001)	0.991
Pregnancy (# of children)	0.000 (-0.001, 0.001)	0.949	0.000 (-0.002, 0.001)	0.712
History of breast feeding	-0.003 (-0.009, 0.003)	0.372	-0.004 (-0.012, 0.005)	0.400
History of estrogen treatment	-0.002 (-0.013, 0.010)	0.781	-0.004 (-0.019, 0.011)	0.573
Telomere length (kb)	-0.000 (-0.001, 0.001)	0.896	0.000 (-0.001, 0.001)	0.844
	Model $R^2=0.026$		Model $R^2=0.008$	

CI confidence interval, NS not significant

Multiple linear regressions adjusted for age, BMI, PASE score in deciles, daily calcium intake, history of smoking, CHD and fracture (for men and women); age of menopause, age of menarche, number of children, history of breast feeding, history of estrogen treatment (women only)

**Table 6** Multiple linear regressions for association between BMDs and tertiled telomere length groups in each of the three age groups

	Age groups	Male		Female	
		Partial $R^2$	$P$	Partial $R^2$	$P$
Baseline BMD		$N=963$		$N=904$	
Hip	65–69	0.003	0.406	0.001	0.599
	70–74	0.016	0.019	0.000	0.925
	≥75	0.000	0.844	0.000	0.798
Femoral neck	65–69	0.001	0.697	0.009	0.083
	70–74	0.013	0.039	0.000	0.955
	≥75	0.002	0.431	0.001	0.640
Change in BMD after 4 years		$N=727$		$N=735$	
Hip	65–69	0.000	0.965	0.003	0.371
	70–74	0.005	0.222	0.003	0.408
	≥75	0.015	0.079	0.001	0.719
Femoral neck	65–69	0.000	0.883	0.001	0.804
	70–74	0.0.03	0.377	0.006	0.236
	≥75	0.008	0.208	0.001	0.764

Multiple linear regressions adjusted for BMI, smoking status, history of CHD and fracture (for men and women); age of menopause, age of menarche, number of children, history of breast feeding, history of estrogen treatment (women only)

NS not significant

bone loss [25, 26], and the need for studies with large sample size and prospective design was pointed out. Our report attempted to continue to address this research question using large numbers of men and women examining changes in BMD prospectively. No association between TL and baseline BMD or changes in BMD was observed, although associations between bone loss and other well-known factors such as age, BMI, physical activity, calcium intake, age of menopause, and estrogen use were observed. This conclusion may appear different from two previous studies [25, 26]. However, many factors should be considered in the comparison between this and previous studies. Firstly, the mean age of this cohort was approximately 72 years, compared with the age range of 71–86 years for men in one study [25] and 48 years for women in the other, although one third of women were postmenopausal [26]. In examining association between TL and BMD, large numbers

of subjects over a wide age range would be preferable. Our cohort did not include young or middle-aged subjects. This fact may also explain the lack of association between TL and age in our study. Secondly, bone loss may vary among different sites, as a result of factors other than biological aging, such as mechanical factors (body weight, physical activity). The contributory role of TL and these other factors may differ depending on the site. For example, mechanical factors and gravity may exert a greater influence in hip BMD compared with forearm. Only hip BMD was available in this study. In the other studies, the association between TL and BMD was only observed in forearm or spine but not in the hip. The findings of this study confirm the lack of association between TL and hip BMD.

Methodological differences in epidemiological studies of telomeres need to be addressed in comparing findings from different studies. We took advantage of the latest method

**Table 7** Logistic regressions for association between clinical osteoporosis at the hip and tertiled telomere length groups in each of the three age groups

Age groups	Telomere length groups	Male ( $N=963$ )		Female ( $N=904$ )	
		OR (95% CI)	$P$	OR (95% CI)	$P$
65–69	TL 1	0.300 (0.059–1.522)	0.146	0.806 (0.358–1.813)	0.602
	TL 2	0.136 (0.014–1.296)	0.083	0.608 (0.257–1.439)	0.258
	TL 3	Reference	–	Reference	–
70–74	TL 1	2.597 (0.474–14.214)	0.271	1.150 (0.511–2.586)	0.736
	TL 2	1.110 (0.168–7.320)	0.914	1.262 (0.545–2.922)	0.587
	TL 3	Reference	–	Reference	–
≥75	TL 1	0.875 (0.328–2.336)	0.789	0.886 (0.416–1.889)	0.755
	TL 2	0.868 (0.328–2.300)	0.776	0.926 (0.430–1.993)	0.844
	TL 3	Reference	–	Reference	–

Logistic regressions adjusted for BMI, smoking status, history of CHD, and fracture (for men and women); age of menopause, age of menarche, number of children, history of breast feeding, history of estrogen treatment (women only)

OR odds ratio, CI confidence interval, NS not significant

of qRT-PCR to measure TL with the benefits of high throughput and sensitivity to TL changes comparable to original TRF analysis [33]. This method allows fast and reliable determination of TL length in such a large-scale epidemiological study. However, it has been pointed out that many methodological issues remain unresolved. The accuracy of the qRT-PCR method (used in this study) versus the southern blot analysis (used in the two previous studies [25, 26]) may be inferior as no study comparing the two methods have been carried out. [39]. Ideally in prospective studies, the rate of change in TL should also be measured in addition to the outcome being examined. The duration of follow-up over which TL changes can be detected is uncertain. The ability of current techniques to detect small changes in TL is uncertain.

In spite of the limitations in laboratory methodology, the strength of this study lies in the large numbers of men and women and the longitudinal design allowing changes in BMD to be examined. Furthermore, it represents the first report in a different racial population with a different lifestyle. Although TL may be a biological marker of bone aging, changes in BMD will be differentially affected by many other genetic and environmental factors between populations. Genetic polymorphisms determining the rate of bone loss may differ between different ethnic groups since there are ethnic differences in cross-sectional association between BMD and genetic polymorphisms [40, 41]. Environmental factors may operate differently according to the BMD site being examined. For example, hip BMD may be more affected by lifestyle differences, being a weight-bearing part of the skeleton.

In conclusion, no association was observed between TL and change in hip BMD in Chinese men and women aged 65 years and over. This finding does not necessarily negate the concept of TL as a biological marker of bone aging, since the age range studied was not wide and BMD at the hip site may be more affected by mechanical factors compared with other sites.

## Conclusion

Leukocyte telomere length is not associated with baseline hip BMD or rate of bone loss in the elderly population of our study. Age itself appears to be the most important determinant of hip BMD and rate of bone loss in this site rather than telomere length.

**Acknowledgments** The study was supported by the Direct Grant from the Chinese University of Hong Kong, the Centre for Nutritional Studies, School of Public Health, and the Hong Kong Jockey Club Charities Foundation.

**Conflicts of interest** None.

## References

- Vogel T, Bitterling H, Dobler T et al (2006) Contemporary diagnostics and therapy of osteoporosis. *Zentralbl Chir* 131:401–406
- Meunier PJ, Delmas PD, Eastell R et al (1999) Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. *International Committee for Osteoporosis Clinical Guidelines. Clin Ther* 21:1025–1044
- Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. *BMJ* 312:1254–1259
- Cauley JA, Hochberg MC, Lui LY et al (2007) Long-term risk of incident vertebral fractures. *JAMA* 298:2761–2767
- Gnudi S, Sitta E, Fiumi N (2007) Bone density and geometry in assessing hip fracture risk in post-menopausal women. *Br J Radiol* 80:893–897
- Cauley JA, Lui LY, Barnes D et al (2008) Successful skeletal aging: a marker of low fracture risk and longevity. The study of osteoporotic fractures (SOF). *J Bone Miner Res* 24(1):134–143
- Leslie WD, Tsang JF, Lix LM (2008) Validation of ten-year fracture risk prediction: a clinical cohort study from the Manitoba Bone Density Program. *Bone* 43:667–671
- Papaioannou A, Kennedy CC, Cranney A et al (2008) Risk factors for low BMD in healthy men age 50 years or older: a systematic review. *Osteoporos Int* 20:507–518
- Aviv A, Levy D, Mangel M (2003) Growth, telomere dynamics and successful and unsuccessful human aging. *Mech Ageing Dev* 124:829–837
- Martens UM, Chavez EA, Poon SSS et al (2000) Accumulation of short telomeres in human fibroblasts prior to replicative senescence. *Exp Cell Res* 256:291–299
- Murnane JP, Sabatier L (2004) Chromosome rearrangements resulting from telomere dysfunction and their role in cancer. *Bioessays* 26:1164–1174
- Pignolo RJ, Suda RK, McMillan EA et al (2008) Defects in telomere maintenance molecules impair osteoblast differentiation and promote osteoporosis. *Aging Cell* 7:23–31
- Goronzy JJ, Fujii H, Weyand CM (2006) Telomeres, immune aging and autoimmunity. *Exp Gerontol* 41:246–251
- van der Harst P, van der Steege G, de Boer RA et al (2007) Telomere length of circulating leukocytes is decreased in patients with chronic heart failure. *J Am Coll Cardiol* 49: 1459–1464
- Magana JJ, Gomez R, Cisneros B et al (2008) Association of interleukin-6 gene polymorphisms with bone mineral density in Mexican women. *Arch Med Res* 39:618–624
- Perez A, Ulla M, Garcia B et al (2008) Genotypes and clinical aspects associated with bone mineral density in Argentine postmenopausal women. *J Bone Miner Metab* 26:358–365
- Styrkarsdottir U, Halldorsson BV, Gretarsdottir S et al (2008) Multiple genetic loci for bone mineral density and fractures. *N Engl J Med* 358:2355–2365
- Tran BN, Nguyen ND, Eisman JA et al (2008) Association between LRP5 polymorphism and bone mineral density: a Bayesian meta-analysis. *BMC Med Genet* 9:55
- Kiel DP, Demissie S, Dupuis J et al (2007) Genome-wide association with bone mass and geometry in the Framingham Heart Study. *BMC Med Genet* 8(Suppl 1):S14
- Richards JB, Rivadeneira F, Inouye M et al (2008) Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. *Lancet* 371:1505–1512
- Takayanagi H, Sato K, Takaoka A et al (2005) Interplay between interferon and other cytokine systems in bone metabolism. *Immunol Rev* 208:181–193



22. Almeida M, Han L, Martin-Millan M et al (2007) Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. *J Biol Chem* 282:27285–27297
23. Sanchez-Rodriguez MA, Ruiz-Ramos M, Correa-Munoz E et al (2007) Oxidative stress as a risk factor for osteoporosis in elderly Mexicans as characterized by antioxidant enzymes. *BMC Musculoskelet Disord* 8:124
24. Altindag O, Erel O, Soran N et al (2008) Total oxidative/antioxidative status and relation to bone mineral density in osteoporosis. *Rheumatol Int* 28:317–321
25. Bekaert S, Van Pottelbergh I, De Meyer T et al (2005) Telomere length versus hormonal and bone mineral status in healthy elderly men. *Mech Ageing Dev* 126:1115–1122
26. Valdes AM, Richards JB, Gardner JP et al (2007) Telomere length in leukocytes correlates with bone mineral density and is shorter in women with osteoporosis. *Osteoporos Int* 18:1203–1210
27. Woo J, Tang NL, Suen E et al (2008) Telomeres and frailty. *Mech Ageing Dev* 129:642–648
28. Lau EM, Chan HH, Woo J et al (1996) Normal ranges for vertebral height ratios and prevalence of vertebral fracture in Hong Kong Chinese: a comparison with American Caucasians. *J Bone Miner Res* 11:1364–1368
29. Washburn RA, Smith KW, Jette AM et al (1993) The Physical Activity Scale for the Elderly (PASE): development and evaluation. *J Clin Epidemiol* 46:153–162
30. Cawthon RM (2002) Telomere measurement by quantitative PCR. *Nucleic Acids Res* 30:e47
31. Gil ME, Coetzer TL (2004) Real-time quantitative PCR of telomere length. *Mol Biotechnol* 27:169–172
32. Norwood D, Dimitrov DS (1998) Sensitive method for measuring telomere lengths by quantifying telomeric DNA content of whole cells. *Biotechniques* 25:1040–1045
33. Baird DM (2005) New developments in telomere length analysis. *Exp Gerontol* 40:363–368
34. Gardner JP, Kimura M, Chai W et al (2007) Telomere dynamics in macaques and humans. *J Gerontol A Biol Sci Med Sci* 62:367–374
35. Strike PW (1991) Statistical methods in laboratory medicine. Chapter 8.9. Measurement and control-precision. Butterworth-Heinemann, Oxford. pp. 273–276.
36. Ho AY, Kung AW (2005) Determinants of peak bone mineral density and bone area in young women. *J Bone Miner Metab* 23:470–475
37. Brouillette SW, Moore JS, McMahon AD et al (2007) Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. *Lancet* 369:107–114
38. Cherkas LF, Hunkin JL, Kato BS et al (2008) The association between physical activity in leisure time and leukocyte telomere length. *Arch Intern Med* 168:154–158
39. Aviv A (2008) The epidemiology of human telomeres: faults and promises. *J Gerontol Med Sci* 63A:979–983
40. Lau EMC, Choy DT, Li M, Woo J, Chung T, Sham A (2004) The relationship between COLIA 1 polymorphisms (SP I) and COLIA 2 Polymorphisms (ECO R1 and Puv II) with bone mineral density in Chinese men and women. *Calcif Tissue Int* 75:133–137
41. Li M, Lau EMC, Woo J (2004) Methylene tetrahydrofolate reductase polymorphism (MTHFR C677T) and bone mineral density in Chinese men and women. *Bone* 35:1369–1374